Hemispherian AS is a Norwegian preclinical pharmaceutical company based in Oslo focused on developing a novel class of small-molecule drugs called GLIX. GLIX compounds target the TET2 enzyme and activate the DNA damage response to induce cancer cell death. The company's lead candidate, GLIX1, is in late-stage preclinical development for glioblastoma, and the company is advancing GLIX5 toward clinical use for platinum-resistant ovarian cancers. The Research Council of Norway awarded Hemispherian a NOK 16 million grant, earmarked for development of drug candidates addressing platinum-resistant ovarian cancers. CEO Zeno Albisser said the team is dedicated to advancing GLIX5 toward clinical use and developing therapies that will make a tangible difference for cancer patients. Hemispherian is a preclinical pharmaceutical company developing a novel class of small molecule drugs called GLIX that target the TET2 enzyme. GLIX compounds activate the DNA damage response, leading to cancer cell death. The company’s lead compound, GLIX1, is in late-stage preclinical development for glioblastoma multiforme. Hemispherian is also developing a companion diagnostic to support patient selection for optimal response to GLIX1. The company is led by CEO Zeno Albisser and is based in Oslo, Norway. It plans to use recent funding to support drug development, expand its preclinical pipeline, and advance its lead therapeutic compounds toward clinical development. Hemispherian is a preclinical pharmaceutical company based in Oslo focused on developing GLIX small-molecule drugs that target the TET2 enzyme and activate the DNA damage response to induce cancer cell death. Its lead asset, GLIX1, is in late-stage preclinical development for the treatment of glioblastoma. The company is led by CEO Zeno Albisser and CSO Adam Robertson, PhD. Hemispherian raised financing to advance GLIX1 into clinical testing. The funds will be used to progress GLIX1 through a phase I and phase II clinical trial. Financial details in the articles indicate a mix of grant and equity financing supporting these development plans. Hemispherian is an Oslo-based preclinical pharmaceutical company developing a novel class of small-molecule drugs called GLIX that target the TET2 enzyme and activate the DNA damage response to induce cancer cell death. Its lead candidate, GLIX1, is in late-stage preclinical development for glioblastoma multiforme. The company is also developing a companion diagnostic to support patient selection for optimal response to GLIX1. Hemispherian intends to use the newly raised funds to expand its drug development activities and its preclinical pipeline and to move lead compounds toward clinical development. The firm recently refreshed its board with new members to support these development efforts.

Total raised

$16M

Funding rounds

5

Latest round

Grant

Latest activity

Dec 2023